| REVIEW ARTICLE |
|
| Year : 2023 | Volume
: 24
| Issue : 1 | Page : 41-49 |
|
|
Beta-blockers in the prevention and treatment of ischemic heart disease: Evidence and clinical practice
Omer Khan1, Murti Patel2, Anna N Tomdio2, Jeffrey Beall1, Ion S Jovin2
1 Department of Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, USA
2 Department of Medicine, Hunter Holmes McGuire VA Medical Center; Department of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
Correspondence Address:
Dr. Ion S Jovin
Department of Medicine, Virginia Commonwealth University, Hunter Holmes McGuire VA Medical Center, 1201 Broad Rock Boulevard Suite 4a-123, Richmond, Virginia 23249
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/heartviews.heartviews_75_22
|
|
|
Coronary artery disease (CAD) is the most prevalent cardiovascular disease characterized by atherosclerotic plaque buildup that can lead to partial or full obstruction of blood flow in the coronary arteries. Treatment for CAD involves a combination of lifestyle changes, pharmacologic therapy, and modern revascularization procedures. Beta-adrenoceptor antagonists (or beta-blockers) have been widely used for decades as a key therapy for CAD. In this review, prior studies are examined to better understand beta-adrenoceptor antagonist use in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting. The evidence for the benefit of beta-blocker therapy is well established for patients with acute myocardial infarction, but it diminishes as the time from the index cardiac event elapses. The evidence for benefit in the perioperative setting is not strong.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
